TVRD
Tvardi Therapeutics, Inc.
NASDAQ: TVRD · HEALTHCARE · BIOTECHNOLOGY
$3.96
-6.94% today
Updated 2026-06-03
Market cap
$25.42M
P/E ratio
—
P/S ratio
559.61x
EPS (TTM)
$-0.27
Dividend yield
—
52W range
$3 – $44
Volume
0.1M
WallStSmart proprietary scores
25
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C6.0
Quality
B3.0
Profitability
D5.0
Valuation
C+2/9
Piotroski F-Score
Weak
-5.7
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$8.29
+109.34%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy4 Buy3 Hold0 Sell1 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.01x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -5.68 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-5.86M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $41.87M | $20.97M | $7.14M | $0.00 | $0.00 |
| Net income | $-85.47M | $-118.51M | $-70.87M | $-18.21M | $-6.80M |
| EPS | — | — | — | — | $-0.27 |
| Free cash flow | $-17.92M | $-23.41M | $-61.96M | $-23.50M | $-5.86M |
| Profit margin | -204.16% | -565.21% | -992.95% | — | — |
Peer comparison
Smart narrative
Tvardi Therapeutics, Inc. trades at $3.96. Our Smart Value Score of 25/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -5.68, it sits in the distress.
Frequently asked questions
What is Tvardi Therapeutics, Inc.'s stock price?
Tvardi Therapeutics, Inc. (TVRD) trades at $3.96, on a P/S of 559.6x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Tvardi Therapeutics, Inc. overvalued?
Tvardi Therapeutics, Inc. carries a Smart Value Score of 25/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Tvardi Therapeutics, Inc. (TVRD)?
The 12-month analyst consensus target is $8.29, about 109.3% above the current $3.96. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Tvardi Therapeutics, Inc.'s Altman Z-Score is -5.68, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio559.61x
ROE-106.44%
Beta—
50D MA$3.32
200D MA$9.13
Shares out0.01B
Float0.01B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—